Characteristics | SPT | NET | PB | Others | P value |
---|---|---|---|---|---|
Age at diagnosis, n (%) | < 0.001 | ||||
≤ 14-year-old | 21 (33.3%) | 19 (28.8%) | 20 (90.9%) | 24 (54.5%) | |
> 14-year-old | 42 (66.7%) | 47 (71.2%) | 2 (9.1%) | 20 (45.5%) | |
Gender, n (%) | < 0.001 | ||||
Female | 57 (90.5%) | 35 (53%) | 10 (45.5%) | 26 (59.1%) | |
Male | 6 (9.5%) | 31 (47%) | 12 (54.5%) | 18 (40.9%) | |
Race, n (%) | 0.569 | ||||
White | 47 (74.6%) | 50 (75.8%) | 14 (63.6%) | 35 (79.5%) | |
Others | 16 (25.4%) | 16 (24.2%) | 8 (36.4%) | 9 (20.5%) | |
Primary sites, n (%) | 0.024 | ||||
Head | 21 (33.3%) | 19 (28.8%) | 8 (36.4%) | 25 (56.8%) | |
Body | 7 (11.1%) | 5 (7.6%) | 2 (9.1%) | 6 (13.6%) | |
Tail | 21 (33.3%) | 17 (25.8%) | 4 (18.2%) | 3 (6.8%) | |
Unknown | 14 (22.2%) | 25 (37.9%) | 8 (36.4%) | 10 (22.7%) | |
Grade, n (%) | < 0.001 | ||||
Low/moderate (I/II) | 20 (31.7%) | 28 (42.4%) | 0 (0%) | 7 (15.9%) | |
Poor/undifferentiated (III/IV) | 1 (1.6%) | 4 (6.1%) | 1 (4.5%) | 5 (11.4%) | |
Unknown | 42 (66.7%) | 34 (51.5%) | 21 (95.5%) | 32 (72.7%) | |
Tumor size (cm), n (%) | 0.065 | ||||
≤ 5 | 7 (11.1%) | 17 (25.8%) | 4 (18.2%) | 10 (22.7%) | |
> 5 | 19 (30.2%) | 9 (13.6%) | 5 (22.7%) | 4 (9.1%) | |
Unknown | 37 (58.7%) | 40 (60.6%) | 13 (59.1%) | 30 (68.2%) | |
SEER stage, n (%) | < 0.001 | ||||
Localized | 45 (71.4%) | 29 (43.9%) | 7 (31.8%) | 14 (31.8%) | |
Regional | 16 (25.4%) | 10 (15.2%) | 4 (18.2%) | 11 (25%) | |
Distant | 2 (3.2%) | 27 (40.9%) | 11 (50%) | 19 (43.2%) | |
Surgery, n (%) | < 0.001 | ||||
Yes | 59 (93.7%) | 38 (57.6%) | 16 (72.7%) | 23 (52.3%) | |
No | 4 (6.3%) | 28 (42.4%) | 6 (27.3%) | 21 (47.7%) | |
Lymph nodes removed, n (%) | < 0.001 | ||||
Yes | 44 (69.8%) | 26 (39.4%) | 6 (27.3%) | 7 (15.9%) | |
No | 19 (30.2%) | 40 (60.6%) | 16 (72.7%) | 37 (84.1%) | |
Chemotherapy, n (%) | < 0.001 | ||||
Yes | 2 (3.2%) | 20 (30.3%) | 11 (50%) | 27 (61.4%) | |
No | 61 (96.8%) | 46 (69.7%) | 11 (50%) | 17 (38.6%) | |
Treatment regimens, n (%) | < 0.001 | ||||
No treatment | 4 (6.3%) | 11 (16.7%) | 2 (9.1%) | 4 (9.1%) | |
Surgery alone | 57 (90.5%) | 35 (53%) | 9 (40.9%) | 13 (29.5%) | |
Chemotherapy alone | 0 (0%) | 17 (25.8%) | 4 (18.2%) | 17 (38.6%) | |
Surgery plus chemotherapy | 2 (3.2%) | 3 (4.5%) | 7 (31.8%) | 10 (22.7%) |